Core One Labs, Inc. · OTC:CLABF
Core One Labs — Investor Presentation (February 2021)
21 slides from Core One Labs's investor presentation, Feb 1, 2021
Slide 1: Core One Labs corporate presentation
CSE:COOL OTC:CLABF February 1, 2021
Slide 2: Disclaimer
DISCLAIMER The information contained in this presentation does not constitute medical advice and is not to be used for treatment purposes or replace consultation with a qualified medical professional. The information presented here is not intended to diagnose health problems or to take the place of
Slide 3: Who We Are?
WHO WE ARE? Core One Labs is a research and development company focused on bringing psychedelic medicine to market through novel delivery systems, the advancement of psychedelic assisted psychotherapy and API grade biosynthetic psilocybin manufacturing. 3
Slide 4: Investment Overview
INVESTMENT OVERVIEW DELIVERY R&D CLINICS OPPORTUNITY SYSTEM • Patent Pending • Patent Pending • Well Funded • Access To 200,000 + Sublingual Biosynthetic Psilocybin Patients Transmucosal • $20M of Invested ‘Thinstrip’ Technology • *cGMP API Grade Capital • Advancement of Psychedelic • Administer Psy
Slide 5: Target Market
EXI S TI N G PS Y C H ED EL I C S C A N B E O PTI MI ZED A S TARGET ME D I C I N ES . MARKET Mental health conditions are on the rise with rapid growth and limited treatments. Current treatments haven’t changed in decades and have proven to be ineffective with undesired side-effects. Psychedelics of
Slide 6: Benefits of Psilocybin
BENEFITS OF PSILOCYBIN 1. Psilocybin with Psychological Support for Treatment Resistant Depression, R. Carhart-Harris, The Lancet 2. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study, M. Bogenshutz, Journal of Psychopharmacology 3. Psilocybin-occasioned mystical-type exp
Slide 7: Our Strategy
PATENT PENDING DELIVERY TECHNOLOGY: Transmucosal Sublingual Thinstrips OUR RESEARCH &DEVELOPMENT: STRATEGY Development of Patentable cGMP API Grade Biosynthetic Psilocybin D e v e lo p and c o mme r c ializ e r ap id o nse t t r e at me nt s c ap ab le o f imp r o v ing me nt al he alt h condit io n
Slide 8: More Than Just a Strip
MORE THAN JUST A STRIP. OUR PATENT PENDING THINSTRIPS PROVIDE AN OPTIMAL DELIVERY METHOD SUITABLE FOR PRECISE DOSING 8
Slide 9: Thinstrips
THINSTRIPS PATEN T PEN DI N G EFFICACY BIOVAILABILITY TEC H N O L O GY & DEL I VERY MEC HAN I SM Our infused thinstrips will allow for efficient bioavailability (absorption) as well as controlled dosing of active ingredients and can be used to CONTROLLED administer multiple API's. RAPID AND PRECISE
Slide 10: Thinstrips
THINSSTRIPS U s i ng o ur pat ent pendi ng Thi ns t ri p t ec hno l o gy , we endeavo ur t o advanc e ps y c hedel i c s as al t ernat i ve m edi c i ne and t o del i ver API s t o c l i ent s i n o ur m edi c al c l i ni c s , as wel l as l i c ens e o ur t ec hno l o gy t o o t her drug pro vi der
Slide 11: R&D: Biosynthetic Psilocybin
R&D: BIOSYNTHETIC PSILOCYBIN Our team has designed and produced a patent pending unique optimized DNA construct and producer strain that allows for time-efficient and cost-effective production of psilocybin at scale. Combined with our patent pending Thinstrips technology, we endeavour to advance psy
Slide 12: R&D: Biosynthetic Advantages
FI N AN C I AL R&D: BIOSYNTHETIC Estimated Market price is $7,000 to $10,000 USD per gram for synthetic psilocybin used in clinical trials. By using our ADVANTAGES biosynthetic expression system, pharma-grade psilocybin can be produced cost effectively for $10s to $100s of dollars. SC I EN TI FI C 1
Slide 13: R&D Revenue Model
R&D REVENUE MODEL 1.) Contract or form a joint venture partnership with a CRO/Manufacturer to produce the API grade psilocybin. The product can then be sold to pharma companies, other API users, and/or other organizations. 2.) Operate a fully owned facility to produce API grade psilocybin. The produ
Slide 14: R&D Completed Milestones
Operating under Health Canada–certified Controlled R&D Substances Licenced lab for production of psilocybin (located in Victoria, BC, Canada)* COMPLETED Lab equipment for research & development has been MILESTONES purchased* Proprietary DNA sequences in final stages of development* Optimized produce
Slide 15: Our Medical Clinics Expansion Plan
OUR MEDICAL CLINICS EXPANSION PLAN Leveraging our existing 2 +200K SOPs, data driven research sets, and practitioner education modules, we will PATIENT CLINICS DATABASE roll out clinics across Vancouver Canada. & West Vancouver 16
Slide 16: Proposed Clinic Model = Recurring Revenue
PROPOSED CLINIC MODEL = RECURRING REVENUE TREATMENT PLANS INTEGRATION THERAPY ONGOING CARE • Approval of the treatment plan • Psychotherapists help patients • Typical treatment is 6 dosing • First dosing session integrate the experiences using sessions with 3 integration • Exploratory Therapy differ
Slide 17: Our Leadership Team
DR. ROBERT HANCOCK Executive Chairman Dr. Hancock is a leading microbiologist in Canada and has researched and taught at the University of British Columbia for nearly 40 years. Dr. Hancock OC, OBC, FRSC, a Canada Research Chair holder in Health and Genomics, a Director of OUR the Centre for Microbia
Slide 18: Industry Comparables
INDUSTRY COMPARABLES NAME FOCUS MOLECULE INTELLECTUAL PROPERTY VALUATION (CAD) PSILOCYBIN, KETAMINE, CORE ONE LABS MULTI DELIVERY TECHNOLOGY $87.5M THC COMPASS PATHWAYS PLC. DRUG DEVELOPMENT PSILOCYBIN CLINICAL TREATMENT *$1.527B CYBIN CORP. MULTI PSILOCYBIN DELIVERY TECHNOLOGY $280.94M FIELD TRIP H
Slide 19: Capital Structure
CAPITAL STRUCTURE Core One Labs Inc. Listings CSE: COOL | OTC: CLABF Price (CAD) $0.91 Issued & Outstanding 96,108,178 Total Warrants 15,497,891 Warrants @ $2.40 750,000 Warrants @ $0.70 10,497,891 Warrants @ $0.30 4,250,000 Market Cap. (CAD) $87.5M All values and figures as at NA Market Close on Fe
Slide 20: Investment Highlights
R&D VALUATION • Patent pending INVESTMENT • Well funded HIGHLIGHTS technology • API Grade • Trading at a discount relative to peers • One of few Health • New management Canada Licensed Dealer Labs DELIVERY CLINICS SYSTEM • Patent Pending • 200,000 + potential patients Thinstrip technology • Developm
Slide 21: Thank You
TH AN K YO U Core One Labs Inc. Suite 3123 – 595 Burrard Street Vancouver, BC V7X 1J1 +1(866) 347-5058 info@core1labs.com
Core One Labs — Investor Presentation (February 2021) on 6ix